Xintela today announced that the company's international patent application directed to the prevention and treatment of degenerative joint diseases using stem cells, including osteoarthritis, has been published.
The data on which the patent application is based are derived from the horse study conducted by Xintela in late 2016. It demonstrated that stem cells, selected using Xintela’s marker technology, protect both joint cartilage and underlying bone following a cartilage injury.
The patent application extends patent protection for Xintela’s stem cell product for the treatment of traumatic joint damage, which may be caused by a sport injury, for example. The stem cell product aims to prevent degradation of joint cartilage and inhibit development of bone sclerosis, which are typical disease related changes in a joint afflicted with osteoarthritis. The application also covers the use of Xintela’s stem cell product for the treatment of degenerative joint diseases, including osteoarthritis and bone sclerosis.
"We are proactively working to broaden and strengthen our patent portfolio in both existing and new areas. In the horse study, we demonstrated that Xintela's selected stem cells have unique properties that make them suitable for both prevention and treatment of osteoarthritis and other degenerative joint diseases, "says Xintela’s CEO, Evy Lundgren-Åkerlund.
The horse study was conducted together with a research group at Cornell University, USA, and will be published in an international scientific journal. The results form an important part of the preclinical documentation for Xintela’s clinical studies in both humans and animals.
About Xintela Xintela develops medical products within regenerative medicine and oncology based on its proprietary marker technology, XINMARK®. Xintela uses the technology to isolate and quality assure stem cells for the treatment of the joint disease osteoarthritis. Studies on horses have shown that the stem cells are safe and that they have a therapeutic effect on the articular cartilage and the underlying bone after an injury. Xintela has recently established its own GMP-facility to produce stem cells for clinical studies. In the oncology program, XINMARK® is used for the development of an antibody-based treatment (Antibody Drug Conjugate, ADC) against specific tumors with first focus on the aggressive brain tumor glioblastoma. Positive preclinical results from cell studies and animal model have shown that the ADC treatment has a targeting and killing effect on specific tumor cells supporting further development of the company’s oncology business. Xintela is listed on Nasdaq First North Stockholm since 22 March 2016. Xintela's Certified Adviser at Nasdaq First North is Erik Penser Bank AB, +46 8-463 80 00.
Below you will find the collected information on Xintela’s press releases, newsletters, diary events, films, media coverage and analyses.
BioStock was given the opportunity to interview Sven Kili in connection with his visit to Sweden for board and strategy work in Xintela.
Dr. Marcus Keep comments on Xintelas glioblastoma project.
Xintelas Chairman of the board and strategic advisor Greg Batcheller, tells us more about Xintelas potential and prospects.
Dr. Lisa Fortier at Cornell University, New York is interviewed by BioStock about Xintelas positive results in horse study.
In the following video interview, Karin explains her role at Xintela and what she considers to be Xintela’s primary strengths.
See the interview with Claes Post, member of the board in Xintela. The interview is in swedish with english subtitles.
See the interview with Sven Kili, member of the board in Xintela. The interview is in English (introduction is in Swedish).
See an interview with Xintela's CEO Evy Lundgren-Åkerlund, after the listing ceremony at Nasdaq First North.
Investor presentation from Lund - Jan 27
Interview with Xintelas CEO